Monthly Archives: June 2013

She Blinded Me With Pseudo-Science*

Vanda Pharmaceuticals had received considerable attention and improved valuation for tasimelteon, whose NDA has been filed in the treatment of circadian rhythm disruption associated with blindness. Now, Adam Feuerstein (Street.com) has outlined in devastating detail what went into the making … Continue reading

Posted in BioFollies, Biotech | Tagged , , | Leave a comment

Lilly and BACE

The termination of LY2886721, Lilly’s BACE inhibitor, probably reverberates louder than it should because it occurs in the context of a seemingly unremitting drumbeat of Alzheimer’s program failures.But Lilly’s statement that they think it was the molecule itself at fault … Continue reading

Posted in Big Pharma, Science | Tagged , , , , | Leave a comment

Neuroscience at GSK: A Tipping Point?

GSK’s formerly vaunted and successful neuroscience programming has been under siege in recent years, with the Company exiting completely from psychiatry, and upper-level support for neurology appearing shaky at best. Now, we fear that GSK may have reached a ‘tipping … Continue reading

Posted in Big Pharma, BioFollies, Science | Tagged , | Leave a comment

Voting for ‘None of the Above’ At Elan

The latest development at Elan is that the Company went to court to block Royalty Pharma‘s buyout bid, which says something about their confidence that they can make the case to their own shareholders. The shareholders deserve something better than … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment